美国局限性甲状腺乳头状癌管理趋势(2000-2018年)
基于18个SEER登记处2000-2018年105,483例首次原发性局限性甲状腺乳头状癌(PTC)患者数据,描述初始治疗的时间趋势。结果显示放射性碘(RAI)使用下降最明显(<4cm PTC从44%降至18%),全甲状腺切除术单用比例上升,而腺叶切除和无手术管理在2015年后变化较细微,儿童患者RAI使用在2009年达峰后显著下降。
要点
- 2006-2018年间<4cm PTC的RAI使用从44%降至18%,微癌2007-2018年从26%降至6%。
- 2000-2018年全甲状腺切除术单用比例从35%升至54%,腺叶切除在2015-2018年从17%升至24%。
- 儿童(<20岁)患者RAI使用2009年达峰59%,2018年降至11%;≥4cm PTC无治疗趋势变化。
核心结论
- 低危成人和儿童PTC中RAI使用下降与ATA指南推荐变化一致,但2015年后腺叶切除和无手术管理的趋势变化比预期更细微,这些趋势可能随安全性证据积累而改变。
研究设计与样本
- 利用18个美国监测、流行病学和最终结果(SEER)登记处2000-2018年数据,描述105,483例首次原发性局限性PTC(无淋巴结/远处转移)患者的初始治疗时间趋势,总体及按人口学和肿瘤特征分层。
主要发现
- RAI使用下降是<4cm PTC管理中最显著的变化,2006-2018年间从44%降至18%,微癌2007-2018年间从26%降至6%。
- 全甲状腺切除术单用比例在2000-2018年间从35%升至54%;腺叶切除在2000-2006年间从23%降至17%,随后稳定,2015-2018年间从17%升至24%。
- 非手术治疗使用无实质性变化,2000-2018年间每年影响<1%的微癌;按性别、年龄、种族/民族、都市与非都市居住地及保险状态分层,治疗趋势相似。
- 儿童患者(<20岁)RAI使用在2009年达峰59%,2018年显著降至11%,全甲状腺切除术单用及程度较轻的腺叶切除增加;≥4cm PTC未观察到治疗趋势变化。
关键数值与推荐
- 2009年和2015年美国甲状腺协会(ATA)成人指南推荐对复发低危PTC采用较不广泛的手术(腺叶切除 vs 全甲状腺切除术)并限制术后RAI使用;2015年建议对部分<1cm PTC(微癌)可考虑主动监测。
- 2015年ATA儿童指南同样转向对低危PTC限制RAI使用。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: In response to evidence of overdiagnosis and overtreatment of papillary thyroid carcinoma (PTC), the 2009 and 2015 American Thyroid Association (ATA) adult guidelines recommended less extensive surgery (lobectomy vs. total thyroidectomy) and more restricted use of postsurgical radioactive iodine (RAI) in management of PTC at low risk of recurrence. In 2015, active surveillance was suggested as a viable option for some <1-cm PTCs, or microcarcinomas. The 2015 ATA pediatric guidelines similarly shifted toward more restricted use of RAI for low-risk PTCs. The impact of these recommendations on low-risk adult and pediatric PTC management remains unclear, particularly after 2015. Methods: Using data from 18 Surveillance, Epidemiology, and End Results (SEER) U.S. registries (2000-2018), we described time trends in reported first-course treatment (total thyroidectomy alone, total thyroidectomy+RAI, lobectomy, no surgery, and other/unknown) for 105,483 patients diagnosed with first primary localized PTC (without nodal/distant metastases), overall and by demographic and tumor characteristics. Results: The declining use of RAI represented the most pronounced change in management of PTCs <4 cm (44-18% during the period 2006-2018), including microcarcinomas (26-6% during the period 2007-2018). In parallel, an increasing proportion of PTCs were managed with total thyroidectomy alone (35-54% during the period 2000-2018), while more subtle changes were observed for lobectomy (declining from 23% to 17% during the period 2000-2006, stabilizing, and then rising from 17% to 24% during the period 2015-2018). Use of nonsurgical management did not meaningfully change over time, impacting <1% of microcarcinomas annually during the period 2000-2018. Similar treatment trends were observed by sex, age, race/ethnicity, metropolitan vs. nonmetropolitan residence, and insurance status. For pediatric patients (<20 years), use of RAI peaked in 2009 (59%), then decreased markedly to 11% (2018), while use of total thyroidectomy alone and, to a lesser extent, lobectomy increased. No changing treatment trends were observed for ≥4-cm PTCs. Conclusions: The declining use of RAI in management of low-risk adult and pediatric PTC is consistent with changing recommendations from the ATA practice guidelines. Post-2015 trends in use of lobectomy and nonsurgical management of low-risk PTCs, particularly microcarcinomas, were more subtle than expected; however, these trends may change as evidence regarding their safety continues to emerge.
引用
- Pasqual E, Sosa JA, Chen Y, et al. Trends in the Management of Localized Papillary Thyroid Carcinoma in the United States (2000-2018). Thyroid. 2022. PMID: 35078347. doi:10.1089/thy.2021.0557
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。